Bactericidal activity of the combination of levofloxacin with rifampin in experimental prosthetic knee infection in rabbits due to methicillin-susceptible Staphylococcus aureus

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 5, 2009, Pages 2145-2148

  Muller Serieys, Claudette ^a   Mghir, Azzam Saleh ^b,d   Massias, Laurent ^a   Fantin, Bruno ^b,c  

^a BICHAT HOSPITAL   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c BEAUJON HOSPITAL   (France)

^d LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

Author keywords

[No Author keywords available]

Indexed keywords

LEVOFLOXACIN; RIFAMPICIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; DRUG POTENTIATION; KNEE PROSTHESIS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MUTANT; NONHUMAN; PRIORITY JOURNAL; PROSTHESIS INFECTION; RABBIT; STAPHYLOCOCCUS AUREUS; VALIDATION PROCESS;

EID: 66149151723     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01163-08     Document Type: Article

References (20)

1. Belmatoug, N., A. C. Crémieux, R. Bleton, A. Volk, A. Saleh-Mghir, M. Grossin, L. Garry, and C. Carbon. 1996. A new model of experimental prosthetic joint infection due to methicillin-resistant Staphyloccus aureus: a microbiologic, histopathologic, and magnetic resonance imaging characterization. J. Infect. Dis. 174:414-417.
2. Blondeau, J., X. Zhao, G. Hansen, and K. Drlica. 2001. Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae, Streptococcus pyogenes, and Staphylococcus aureus. Antimicrob. Agents Chemother. 45:433-438. (Pubitemid 32105277)
3. Chow, A., C. Fowler, R. R. Williams, N. Morgan, S. Kaminski, and J. Natarajan. 2001. Safety and pharmacokinetics of multiple 750-millingram doses of intravenous levolfoxacin in healthy volunteers. Antimicrob. Agents Chemother. 45:2122-2125. (Pubitemid 32591709)
4. Chuard, C., M. Herrmann, P. Vaudaux, F. A. Wadvogel, and D. P. Lew. 1991. Successful therapy of experimental chronic foreign-body infection due to methicillin-resistant Staphylococcus aureus by antimicrobial combinations. Antimicrob. Agents Chemother. 35:2611-2616.
5. 14C]sparfloxacin in experimental Staphylococcus aureus joint prosthetis infection. Antimicrob. Agents Chemother. 40:2111-2116.
6. Croisier, D., M. Etienne, E. Bergoin, P. E. Charles, C. Lequeu, L. Piroth, H. Portier, and P. Chavanet. 2004. Mutant selection window in levofloxacin and moxifloxacin treatments of experimental pneumococcal pneumonia in a rabbit model of human therapy. Antimicrob. Agents Chemother. 48:1699-1707. (Pubitemid 38544377)
7. Croom, F. K., and K. L. Goa. 2003. Levofloxacin: a review of its use in the treatment of bacterial infections in the United States. Drugs 63:2769-2802. (Pubitemid 38049994)
8. Drancourt, M., A. Stein, J. N. Argenson, A. Zannier, G. Curvale, and D. Raoult. 1993. Oral rifampin plus ofloxacin for treatment of Staphylococcus- infected orthopaedic implants. Antimicrob. Agents Chemother. 37:1214-1218.
9. European Commission. 1986. Directive for the protection of vertebrate animals used for experiments and other scientific purposes (86/609/EEC). Off. J. Eur. Comm. L 358:1-29.
10. Fantin, B., and C. Carbon. 1992. In vivo antibiotic synergism: contribution of animal models. Antimicrob. Agents Chemother. 36:907-912.
11. Lucet, J. C., M. Herrmann, P. Rohner, R. Auckenthaler, F. A. Wadvogel, and D. P. Lew. 1990. Treatment of experimental foreign body infection caused by methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 34:2312-2317.
12. Metallidis, S., D. Topsis, J. Nikolaidis, E. Alexiadou, G. Lazaraki, L. Grovaris, A. Theodoridou, and P. Nikolaidis. 2007. Penetration of moxifloxacin and levofloxacin into cancellous and cortical bone in patients undergoing totl hip arthroplasty. J. Chemother. 19:682-687.
13. Murillo, O., A. Doménech, A. Garcia, F. Tubau, C. Cabellos, F. Gudiol, and J. Ariza. 2006. Efficacy of high doses of levofloxacin in experimental foreign-body infection by methicillin-susceptible Staphylococcus aureus. Antimicrob. Agents Chemother. 50:4011-4017.
14. Norden, C. W. 1988. Lessons learned from animal models of osteomyelitis. Rev. Infect. Dis. 10:103-110.
15. Preston, S. L., G. L. Drusano, A. L. Berman, C. L. Fowler, A. T. Chow, B. Dornseif, V. Reichl, J. Natarajan, and M. Corrado. 1998. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA 279:125-129. (Pubitemid 28068302)
16. Sendi, P., M. Rohrbach, P. Graber, R. Frei, P. E. Ochsner, and W. Zimmerli. 2006. Staphylococcus aureus small colony variants in prosthetic joint infection. Clin. Infect. Dis. 43:961-967.
17. Vaudaux, P., P. Francois, C. Bisognano, J. Schrenzel, and D. P. Lew. 2002. Comparison of levofloxacin, alatrofloxacin and vancomycin for prophylaxis and treatment of experimental foreign-body-associated infection by methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 46:1503-1509. (Pubitemid 34415334)
18. Zarrouk, V., B. Bozdogan, R. Leclercq, L. Garry, C. Feger, C. Carbon, and B. Fantin. 2001. Activities of the combination of quinupristin-dalfopristin with rifampin in vitro and in experimental endocarditis due to Staphylococus aureus strains with various phenotypes of resistance to macrolide-lincosamide- streptomramin antibiotics. Antimicrob. Agents Chemother. 45:1244-1248.
19. Zimmerli, W., A. F. Widmer, M. Blatter, R. Frei, and P. E. Ochsner. 1998. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections. JAMA 279:1537-1541.
20. Zimmerli, W., A. Trampuz, and P. E. Ochsner. 2004. Prosthetic-joint infections. N. Engl. J. Med. 351:1645-1654. (Pubitemid 39350440)